CAR-T
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy that uses the body’s own immune system to fight cancer. CAR-T cells are engineered to recognize and attack cancer cells, and they have been shown to be effective in treating a variety of different types of cancer, including leukemia, lymphoma, and myeloma.
CAR-T therapy is a complex and expensive treatment, but it has the potential to offer long-term remission for patients with cancer who have not responded to other treatments. In 2017, the FDA approved the first CAR-T therapy for the treatment of leukemia, and since then, several other CAR-T therapies have been approved for the treatment of different types of cancer.
Here’s a roundup of STAT coverage on a promising avenue of health and science research, including side effects and costs.
Latest
STAT Plus: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
STAT Plus: Now 18, the first child to ever receive CAR-T cancer therapy is ready for a new identity
Virtual Event: CAR-T comes of age?
STAT Plus: New data on CRISPR Therapeutics’ off-the-shelf CAR-T cancer therapy shows more remissions, no major safety issues
STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
